Immune 'control switch' could prevent brain injury in premature babies

October 30, 2019

Researchers have discovered an immune control switch that could protect the brains of premature babies, who often suffer brain injuries when their immune response goes into overdrive.

Through a series of clinical and pre-clinical studies, an international research team has for the first time worked out how to calm down hyperactive microglia, the brain's immune cells.

The research points to a potential treatment for reducing brain injury in premature babies, showing microglia could be successfully targeted with drugs to control their harmful overactive behaviour.

The research, conducted over seven years by scientists and clinicians from Australia, France, the United Kingdom, Germany, Singapore and Sweden, is published in the journal Brain.

About 15 million babies are born prematurely around the world each year and rates of preterm birth are increasing in developed countries. In Australia, around 8% of babies are born prematurely (before 37 weeks gestation).

Premature birth is the most common cause of death and disability in children under 5 and up to 60% of babies born too early will have lifelong problems including attention-deficit disorders, autism, cerebral palsy and epilepsy.

Senior co-author, RMIT University's Dr Bobbi Fleiss, said previous research had shown that exposure to inflammation was a driver of both premature birth and brain injury in babies.

"Inflammation is our body's natural way of fighting infection, but the immune cells that drive this response can react too strongly in the developing brain and go into hyperdrive," Fleiss, a Vice-Chancellor's Research Fellow at RMIT, said.

"This intense immune response not only damages the baby's brain, it diverts those cells from their other job of supervising brain development.

"We've discovered a way to tone down the hyperactivity without affecting the critical brain building work, using a microglia targeted therapeutic approach.

"It's incredibly exciting because until now, we've known so little about the mechanisms that control the behaviour of microglia.

"This discovery gives us a solid way forward for developing new brain-protective therapies that will help millions of premature babies, and their families, around the world."

Senior co-author, Professor Pierre Gressens from Inserm and the University of Paris, said doctors currently had no treatment options for stopping or preventing brain injury in premature babies.

"Inflammatory activation of microglia in the developing brain is associated with permanent neurological impacts in 9 million preterm babies around the globe every year," Gressens said.

"There is a lot more work ahead to develop our treatment for clinical use, but these findings bring us significantly closer to delivering life-changing therapies for these vulnerable infants."

Protecting white matter

When microglia go into overdrive, they harm the brain's white matter - a protective cocoon of fat that insulates nerve fibres and helps electrical signals move around the brain and body quickly and effectively.

If there is not enough white matter or if it is damaged, nerve pulses travel too slowly, affecting movement and cognition.

Pathway to treatment

The key to controlling the harmful behaviour of the microglia is a signalling pathway known as the Wnt.

In animal trials, researchers tested a drug that targets the Wnt pathway and keeps it active during inflammation.

The treatment prevented the microglia's harmful hyperactivity, reducing damage to white matter as well as long-term memory problems associated with preterm birth.

Genetic differences

The research also revealed that in premature babies, genetic differences in the Wnt pathway are linked with different levels of brain connectivity and white matter structure.

This natural variance could in future be used for prognosis, to help doctors predict which premature babies may need extra support through their lives to overcome cognitive or physical problems.

Global collaboration

The collaboration involved clinicians and scientists from King's College London, Institut Pasteur, Universite? Paris Descartes, PremUP, Pitie? Salpe?trie?re Hospital, Universite? Paris 13, Conservatoire National des arts et me?tiers, Guy's and St Thomas' NHS Foundation Trust, University of Edinburgh, Max Delbrueck Center for Molecular Medicine in the Helmholtz Society, Centre Hospitalier Sainte Anne, Duke-NUS Medical School and Gothenburg University.

The researchers acknowledge the support of Genisphere LLC (Hatfield PA, USA), developers of a DNA-based targeted drug delivery platform used in the trials. The novel 3DNA nanocarrier was shown to carry the drug through the body and precisely target the microglia.

RMIT has recently signed an agreement with Genisphere to further the research, with the aim of translating the findings into clinical therapies.
-end-
The research was funded in part by the Cerebral Palsy Alliance.

"Decreased microglial Wnt/β-catenin signalling drives microglial pro-inflammatory activation in the developing brain" is published in Brain (DOI: 10.1093/brain/awz319).

RMIT University

Related Immune Response Articles from Brightsurf:

Boosting chickens' own immune response could curb disease
Broiler chicken producers the world over are all too familiar with coccidiosis, a parasite-borne intestinal disease that stalls growth and winnows flocks.

Cells sacrifice themselves to boost immune response to viruses
Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Children's immune response more effective against COVID-19
Children and adults exhibit distinct immune system responses to infection by the virus that causes COVID-19, a finding that helps explain why COVID-19 outcomes tend to be much worse in adults, researchers from Yale and Albert Einstein College of Medicine report Sept.

Which immune response could cause a vaccine against COVID-19?
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

Obesity may alter immune system response to COVID-19
Obesity may cause a hyperactive immune system response to COVID-19 infection that makes it difficult to fight off the virus, according to a new manuscript published in the Endocrine Society's journal, Endocrinology.

Immune response to Sars-Cov-2 following organ transplantation
Even patients with suppressed immune systems can achieve a strong immune response to Sars-Cov-2.

'Relaxed' T cells critical to immune response
Rice University researchers model the role of relaxation time as T cells bind to invaders or imposters, and how their ability to differentiate between the two triggers the body's immune system.

A novel mechanism that triggers a cellular immune response
Researchers at Baylor College of Medicine present comprehensive evidence that supports a novel trigger for a cell-mediated response and propose a mechanism for its action.

Platelets exacerbate immune response
Platelets not only play a key role in blood clotting, but can also significantly intensify inflammatory processes.

How to boost immune response to vaccines in older people
Identifying interventions that improve vaccine efficacy in older persons is vital to deliver healthy ageing for an ageing population.

Read More: Immune Response News and Immune Response Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.